Lupin gets USFDA nod for generic equivalet of Dilantin
Extended Phenytoin Sodium Capsules USP,100 mg (RLD: Dilantin) had annual sales of approximately USD 105 million in the U.S. (IQVIA MAT June 2019), Lupin said.
New Delhi: Pharma major Lupin Limited (Lupin) recently announced that it has received approval for its Extended Phenytoin Sodium Capsules USP, 100 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Dilantin 100 mg, of Parke-Davis, division of Pfizer Inc.
Lupin’s Extended Phenytoin Sodium Capsules USP, 100 mg, are indicated for:
- Treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
- Prevention and treatment of seizures occurring during or following neurosurgery
Read Also: Lupin unveils a generic version of CellCept in the US
Extended Phenytoin Sodium Capsules USP,100 mg (RLD: Dilantin) had annual sales of approximately USD 105 million in the U.S. (IQVIA MAT June 2019).
Headquartered in Mumbai, the company is a significant player in Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a global leadership position in the Anti-TB segment.
Read Also: Lupin Mandideep facility red-flagged by USFDA for CGMP violations
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd